Detalles de la búsqueda
1.
Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis.
Antimicrob Agents Chemother;
68(5): e0158423, 2024 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38526046
2.
Activity of aztreonam-avibactam against Enterobacterales resistant to recently approved beta-lactamase inhibitor combinations collected in Europe, Latin America, and the Asia-Pacific Region (2020-2022).
Int J Antimicrob Agents;
63(4): 107113, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38354826
3.
In vitro activity of manogepix and comparators against infrequently encountered yeast and mold isolates from the SENTRY Surveillance Program (2017-2022).
Antimicrob Agents Chemother;
68(2): e0113223, 2024 Feb 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38205999
4.
Use of isavuconazole antifungal medicine to treat mold infections in Asia and the Western Pacific region: a plain language summary.
Future Microbiol;
19: 173-180, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38018423
5.
Plain language summary: Did the COVID-19 pandemic change the resistance to current antifungal medicines?
Future Microbiol;
19: 85-90, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37861300
6.
Trends in the susceptibility of U.S. Acinetobacter baumannii-calcoaceticus species complex and Stenotrophomonas maltophilia isolates to minocycline, 2014-2021.
Microbiol Spectr;
11(6): e0198123, 2023 Dec 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37921464
7.
Susceptibility patterns of amphotericin B, itraconazole, posaconazole, voriconazole and caspofungin for isolates causing invasive mould infections from the SENTRY Antifungal Surveillance Program (2018-2021) and application of single-site epidemiological cutoff values to evaluate amphotericin B activity.
Mycoses;
66(10): 854-868, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37431241
8.
Evaluation of XGEN Multi Sepsis Flow Chip Molecular Assay for Early Diagnosis of Bloodstream Infection.
Curr Microbiol;
80(7): 231, 2023 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37261596
9.
In Vitro Activity of Isavuconazole and Other Mould-Active Azoles against Aspergillus fumigatus with and without CYP51 Alterations.
J Fungi (Basel);
9(6)2023 May 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-37367544
10.
Recent increase in fluconazole-nonsusceptible Candida parapsilosis in a global surveillance with the expansion of the Erg11 Y132F genotype and a rapid detection method for this alteration.
Diagn Microbiol Infect Dis;
106(3): 115957, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37167652
11.
Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug-resistant Enterobacterales from United States Medical Centers (2018-2022).
Diagn Microbiol Infect Dis;
106(2): 115945, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37060707
12.
Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019-2021).
Open Forum Infect Dis;
10(2): ofad046, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36846612
13.
Comparative activity of newer ß-lactam/ß-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
Int J Antimicrob Agents;
61(4): 106744, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36738849
14.
Antimicrobial activity of ceftibuten-avibactam against a global collection of Enterobacterales from patients with urinary tract infections (2021).
Eur J Clin Microbiol Infect Dis;
42(4): 453-459, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36810724
15.
Antifungal Activity of Isavuconazole and Comparator Agents against Contemporaneous Mucorales Isolates from USA, Europe, and Asia-Pacific.
J Fungi (Basel);
9(2)2023 Feb 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36836355
16.
Performance of the Vitek 2 Advanced Expert System (AES) as a Rapid Tool for Reporting Antimicrobial Susceptibility Testing (AST) in Enterobacterales from North and Latin America.
Microbiol Spectr;
11(1): e0467322, 2023 02 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-36645286
17.
Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA, Europe, Latin America, and the Asia-Pacific region (2015-2019).
Diagn Microbiol Infect Dis;
104(4): 115804, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36170792
18.
Five-year analysis of the in vitro activity of tedizolid against a worldwide collection of indicated species causing clinical infections: results from the Surveillance of Tedizolid Activity and Resistance (STAR) programme.
JAC Antimicrob Resist;
4(5): dlac088, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36072303
19.
Antimicrobial Activity of Ceftaroline and Comparator Agents Against Ceftriaxone-Nonsusceptible Streptococcus pneumoniae from the United States (2008-2020).
Microb Drug Resist;
28(9): 935-940, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35976086
20.
Evaluation of the Post-Antifungal Effect of Rezafungin and Micafungin against Candida albicans, Candida parapsilosis and Candida glabrata.
Mycoses;
65(11): 1040-1044, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-35778886